Photo of Daniel Soffer

Daniel Soffer

  • SENIOR FACULTY Medicine, Cardiology
Print ProfilePrint Profile


    Dr. Soffer recently joined Mount Sinai Hospital after 7 years at Lenox Hill Hospital where he worked as a member of the interventional coronary, peripheral and structural heart teams. Dr. Soffer trained at the world renowned William Beaumont Hospital in Royal Oak, Michigan followed by a two year tenure in North Carolina where he stamped his expertise in cardiac, carotid and peripheral interventions. He completed his residency and his cardiology fellowship programs at Lenox Hill Hospital and he is currently board certified in Cardiovascular Disease, Interventional Cardiology and Endovascular Medicine.

    Dr. Soffer brought with him extensive experience in primary angioplasty for acute myocardial infarction from Michigan and North Carolina where his program was the regional center for a tri-state area. In Michigan, Dr. Soffer participated in the first TandemHeart®, a percutaneous left ventricular assist device, performed in the United States. In North Carolina, he assembled a team of vascular surgeons and interventional radiologists to create a successful carotid stent program. At that time he was one of the first physicians in the country to use the first atherectomy device, (SilverHawk made by Fox Hollow), in patients with lower extremity claudication and critical limb ischemia.

     In addition to high risk coronary interventions and carotid stenting Dr. Soffer performs limb salvage procedures using thrombectomy and all atherectomy devices available in the United States. He also has an abiding interest in reno-vascular disease and refractory hypertension, in particular renal artery stenosis, and performs percutaneous interventions to treat these conditions. Dr. Soffer’s other areas of expertise include percutaneous closure of patent foramen ovale (PFO) in patients who had a cryptogenic stroke, closure of atrial septal defect (ASD), and percutaneous balloon valvuloplasty of the aortic and mitral valves.

     Dr. Soffer has been the co-investigator in numerous clinical trials assessing new techniques and devices in the coronary, carotid and peripheral circulation as well as structural heart disease. He is a fellow of the American College of Cardiology and The Society for Cardiac Angiography and Interventions and was selected as one of America’s top physicians by the Consumers’ Research Council of America and as the Cambridge professional of the year in Cardiovascular Medicine.


Primary Investigator, Evaluation of the Cascade Abrazo Analyzer and DTM (Direct Thrombin Monitor) Test Card Bivalirudin (“Abrazo DTM”), Sponsored by Helena Labs.
Primary Investigator, ORBIT II Pivotal Trial to Evaluate the Safety and Efficacy of the Diamondback 360°® Orbital Atherectomy System in Treating De Novo, Severely Calcified Coronary Lesions, Sponsored by Cardiovascular Systems Inc. (CSI).

SUPERB Comparison of the Supera PERipheral System to a Performance Goal derived from Balloon Angioplasty Clinical Trials in the Superficial Femoral Artery, Sponsored by IDEV Technologies, Inc.

Choice  Carotid Stenting For High Surgical Risk Patients; Evaluating Outcomes Through The CollectIon Of Clinical Evidence


Protect  Protected Carotid Artery Stenting in Subjects at High Risk for CEA

Proguard   Trial- Protection During Carotid Stenting in High Risk Patients with the TriActive ProGUARD System

VIVA Trial - VIVEXX™ Carotid Revascularization for High Surgical Risk Patients with Extracranial Carotid Artery Stenosis using the Bard® VIVEXX™ Carotid Stent and Emboshield® Bare Wire™ Rapid Exchange Embolic Protection System.

MAVERIC III – Medtronic Evaluation of the Medtronic AVE Self-Expanding Carotid Stent System with Distal Protection in the Treatment of Carotid Stenosis

Tracer - A Multi-center, Randomized, Double-Blind, Placebo- Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects With Acute Coronary Syndrome: Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA•CER).

Zomaxx II - Trial-A Randomized, Controlled Trial to Evaluate the Safety and Efficacy of the Zomaxx™ Drug Eluting Coronary Stent System as Compared to the Taxus™ Express2™ Paclitaxel-Eluting Stent in de novo Coronary Artery Lesions

Gravitas  Gauging Responsiveness with A VerifyNow assay- Impact on Thrombosis And Safety

Xience    XIENCE™ V Everolimus Eluting Coronary Stent System (EECSS) USA Post-Approval Study

Reform  REFORM- Evaluation of Effectiveness and Safety of the Formula™ Balloon-Expandable Stent for Renal Artery Stenosis

Endeavor SVS   A Clinical Evaluation of the Medtronic Endeavor Zotarolimus-Eluting Coronary Stent System in the Treatment of Single De novo Lesions in Small Diameter Native Coronary Arteries (Endeavor SVS)

Resolute  A Clinical Evaluation of the Medtronic Endeavor® Resolute Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Native Coronary Arteries with a Reference Vessel Diameter of 2.25 mm to 4.2 mm - The Medtronic RESOLUTE US Clinical Trial

Realism  EVEREST II Continued Access Registry 

Intense  Iliac artery treatmeNT with thE iNvatec Scuba cobalt chromium stEnt (INTENSE) Study

Liberte  TAXUS Libertē Post-Approval Study

Superb Comparison of the SUpera® PERipheral System to a Performance Goal derived from Balloon Angioplasty Clinical Trials in the Superficial Femoral Artery (The SUPERB Study)

Dapt   A prospective, multi-center, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy (DAPT) in subjects undergoing percutaneous coronary intervention (PCI) with either drug-eluting stent (DES) or bare metal stent (BMS) placement for the treatment of coronary artery lesions.

FREEDOM Trial – Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multivessel Disease

DELTA MI Trial – Direct Inhibition of Protein Kinase C Enzyme to Limit Total Infarct Size in Acute Myocardial Infarction

PREMIUM Trial- Prospective Randomized Investigation to Evaluate Incidence of Headache Reduction in Subjects with Migrane and Patent Foramen Ovale Using the AMPLATZER PFO Occluder Compared to Medical Management

AMEthyst Trial – A Prospective, Multicenter, Randomized Study to Evaluate the Safety and Efficacy of the Interceptor Embolic Protection Device During Transluminal Percutaneous Coronary Interventions on Saphenous Grafts

EVENT Registry- A Multicenter Registry for the Evaluation of Drug Eluting Stents and Ischemic Events

DYNAMIC Registry- Dynamic Evaluation of Percutaneous Intervention

ASPIRE Trial- Angioplasty in SVG’s with Post Intervention Removal of Embolic Debris 

ZILVER Trial – Evaluation of the Zilver® PTX™ Vascular Stent in the Above-the-Knee Femoro-popliteal Artery Clinical Study Protocol: Phase I

SIRIUS Trial - A Multicenter, Randomized, Double-Blind study of the SIROLIMUS Coated Bx VELOCITY Stent in the Treatment of Patients with de-novo Coronary Artery Lesions

CARDIOSEAL - Septal Occlusion System Registry

TRAP - Vascular Filtration System Trial – Randomized Study of TRAP Filter Device in Saphenous Vein Graft PTCA/Stenting

A Phase II Randomized Multicenter Clinical Study To Evaluate the Safety and Efficacy of the TandemHeart pVAD System vs. Conventional Therapy for Treatment of Cardiogenic Shock

TherOx AO System AMIHOT Trial – Acute Myocardial Infarction with Hyperoxemic Therapy

FIRE Trial- Distal Protection with BSC/EPI Filterwire vs. PercuSurge Guardwire During SVG Stenting

COOL-MI Trial - Hypothermia as an Adjunctive Therapy to PTCA in Patients with Acute MI

BARRICADE Trial – PCI with the JOMED PTFE Covered Stent in Degenerated Saphenous Vein Grafts


Haden G, Polenta S, Jelnin V, Soffer D, Hecht H. Images in cardiology: postpartum intramural hematoma-evaluation by computed tomographic angiography. Journal of clinical hypertension (Greenwich, Conn.) 2009 Nov; 11(11).

Chiam PT, Roubin GS, Iyer SS, Green RM, Soffer DE, Brennan C, Vitek JJ. Carotid artery stenting in elderly patients: importance of case selection. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2008 Sep; 72(3).

Hanzel G, Balon H, Wong O, Soffer D, Lee DT, Safian RD. Prospective evaluation of aggressive medical therapy for atherosclerotic renal artery stenosis, with renal artery stenting reserved for previously injured heart, brain, or kidney. The American journal of cardiology 2005 Nov; 96(9).

Soffer D, Moussa I, Harjai KJ, Boura JA, Dixon SR, Grines CL, O'Neill WW, Roubin GS, Moses JW. Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: do we need more aggressive dosing regimens in unstable angina?. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 2003 May; 59(1).

Soffer D, Moussa I, Karatepe M, Harjai KJ, Boura J, Dixon SR, Grines CL, O'Neill WW, Roubin GS, Moses JW. Suboptimal inhibition of platelet aggregation following tirofiban bolus in patients undergoing percutaneous coronary intervention for unstable angina pectoris. The American journal of cardiology 2003 Apr; 91(7).

Polena S, Gupta MP, Shaikh H, Zazzali K, Coplan N, Gintautas J, Labana SS, Soffer D. Platelet aggregation inhibition in patients receiving statins either fully or partially metabolized by CYP3A4. Proceedings of the Western Pharmacology Society 2008; 51.

Soffer D, Polena S, Zazzali K, Shaikh H, Goyal R, Kossidas K, Carville D. Comparison of a Point-of-Care Platelet Function Testing to Light Transmission Aggregometry in Patients Undergoing Percutaneous Coronary Intervention Pretreated With Aspirin and Clopidogrel . Point of Care 2011;: 35-39.

Soffer D, O'Neill WW, Harjai KJ, Boura J, Safian RD, Grines C, Moussa I, Roubin GS, Moses JW. Inter-assay Variability in the Degree of Platelet Inhibition Following GPIIb/IIIa Receptor Blockade in Patients Undergoing Coronary Intervention: A Comparison of Three Different Point-of-Care Assays. Presented at the 51th annual session of the American College of Cardiology 2002;.

Soffer D, Lee DT, Balon H, Barnhart S, Boura J, Dixon S, O'Neill WW, Safian RD. Renal Stenting Preserves Single Kidney GFR and Renal Mass Compared to Medical Therapy in Patients with Renal Artery Stenosis: 17 Months Follow-up. Presented at the Transcatheter and Cardiovascular Therapeutics, Washington DC 2002;.

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Soffer did not report having any of the following types of financial relationships with industry during 2014 and/or 2015: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

Edit profile in Sinai Central


485 Madison Avenue
Suite 17A
New York, NY 10022

Tel: 212-752-2700
Fax: 212-731-3739